Physician profile
Mark Druck
NPI 1124109178
$28,639.54
in general payments reported to CMS, 2019-2025
70 companies · $2,622 in 2025
The $2,622 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,627 · 2020: $5,295 · 2021: $4,058 · 2022: $2,732 · 2023: $5,681 · 2024: $2,625 · 2025: $2,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,193 · Consulting Fee: $2,730 · Education: $4.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,192.91 |
| Consulting Fee | $2,730.00 |
| Education | $4.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,893.72 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $3,481.58 | 2019-2025 | Erleada, Darzalex, Talvey |
| Gilead Sciences, INC. | $3,469.07 | 2019-2025 | Trodelvy |
| Abbvie INC. | $2,092.33 | 2020-2025 | Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,373.65 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,245.32 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $1,187.60 | 2020-2025 | |
| Incyte Corporation | $1,106.57 | 2019-2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $1,025.18 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Pfizer INC. | $980.84 | 2019-2025 | |
| Amgen INC. | $539.64 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Daiichi Sankyo INC. | $525.90 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Astellas Pharma US INC | $457.05 | 2020-2025 | Padcev, Xtandi, Vyloy |
| Deciphera Pharmaceuticals INC. | $429.93 | 2021-2023 | Qinlock |
| Lilly USA, LLC | $387.37 | 2019-2025 | Verzenio, Jaypirca |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $378.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $350.84 | 2019-2025 | Libtayo |
| Seagen INC. | $300.03 | 2021-2023 | Padcev, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $299.10 | 2019-2025 | Ninlaro, Iclusig, Alunbrig |
| Kite Pharma, INC. | $280.47 | 2019-2023 | |
| Celgene Corporation | $274.68 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Mirati Therapeutics, INC. | $238.73 | 2023-2024 | Krazati |
| Glaxosmithkline, LLC. | $237.60 | 2021-2025 | Zejula, Jemperli, Blenrep |
| Exelixis INC. | $167.59 | 2022-2025 | Cabometyx |
| Beigene USA, INC. | $156.56 | 2021-2025 | Brukinsa |
| Genentech USA, INC. | $155.29 | 2020-2025 | Tecentriq, Venclexta, Alecensa |
| Myriad Genetic Laboratories, INC. | $146.90 | 2021-2023 | Precisetumor |
| Ge Healthcare | $144.77 | 2022 | |
| Genzyme Corporation | $140.79 | 2019-2025 | |
| Tersera Therapeutics LLC | $127.13 | 2024-2025 | Xermelo, Zoladex |
| Allergan, INC. | $124.99 | 2019 | |
| Sumitomo Pharma America, INC. | $123.54 | 2023-2025 | Orgovyx |
| Array Biopharma INC | $114.05 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Pharmacosmos Therapeutics INC. | $100.32 | 2024-2025 | Monoferric |
| Pharmacyclics LLC, An Abbvie Company | $99.06 | 2019-2023 | Epkinly, Imbruvica |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.76 | 2019-2022 | |
| Emd Serono, INC. | $96.03 | 2019-2025 | Bavencio |
| Tempus Ai, INC | $87.03 | 2024 | |
| Taiho Oncology, INC. | $79.12 | 2024-2025 | |
| Genmab U.S., INC. | $78.57 | 2023-2024 | Tivdak |
| Agios Pharmaceuticals, INC. | $76.59 | 2024-2025 | Pyrukynd |
| Myovant Sciences INC. | $75.20 | 2021-2022 | |
| Cti Biopharma Corp. | $72.09 | 2023 | Vonjo |
| Novocure INC. | $70.10 | 2023-2025 | Optune Lua (Novottf-200t) |
| Adaptive Biotechnologies Corporation | $69.29 | 2022-2024 | Clonoseq |
| Stemline Therapeutics INC. | $67.15 | 2025 | Orserdu |
| Beone Medicines USA, INC. | $58.31 | 2025 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $48.36 | 2022-2025 | |
| Puma Biotechnology, INC. | $41.05 | 2019-2025 | |
| Roche Diagnostics Corporation | $39.29 | 2019 | |
| Caris Mpi, INC. | $38.27 | 2025 | Mi Cancer Seek |
| Emmaus Medical, INC. | $37.58 | 2024 | Endari |
| Pharmaessentia USA Corporation | $31.80 | 2023-2024 | Besremi |
| Blueprint Medicines Corporation | $31.80 | 2023 | Ayvakit |
| Jazz Pharmaceuticals INC. | $31.02 | 2024 | |
| Recordati_rare_diseases_inc. | $28.99 | 2023-2024 | Sylvant |
| Heron Therapeutics, INC. | $26.70 | 2019 | |
| Macrogenics, INC. | $18.57 | 2023 | |
| Legend Biotech USA INC. | $18.53 | 2025 | Carvykti |
| G1 Therapeutics, INC. | $18.43 | 2023 | Cosela |
| Flowonix Medical Incorporated | $17.56 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.75 | 2025 | Danziten |
| Geron Corporation | $16.33 | 2025 | Rytelo |
| Coherus Oncology, INC. | $15.27 | 2023 | |
| Alnylam Pharmaceuticals INC. | $15.08 | 2023 | Givlaari |
| Rigel Pharmaceuticals, INC. | $13.89 | 2022 | |
| Global Blood Therapeutics, INC. | $13.58 | 2022 | |
| Tg Therapeutics, INC. | $13.02 | 2021 | |
| Sobi, INC | $12.18 | 2022 | |
| Sun Pharmaceutical Industries INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Druck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.